Liver Cancer Treatment in China: What Function Changes, What NanoKnife Ads Don't
Most liver-cancer files in China are HBV-related HCC plus liver-function math. IARC 2024: 354,143 new cases and 303,783 deaths. CARES-310 reported OS 23.8 vs 15.2 months for a China-approved combination. Transplant is not a tourist product. Send triphasic imaging and Child-Pugh labs. About 24 hours. No obligation to book.
Average reply: 24 hoursNo obligation to book
HBV + functionnot a logo
OS 23.8 vs 15.2CARES-310
No tourist transplantallocation rules
Quick answer
Most liver-cancer files in China are HBV-related HCC plus liver-function math. IARC GLOBOCAN 2024: 354,143 new cases and 303,783 deaths (second after lung). Ablation is for selected small tumours, not a chemo substitute. Transplant is not a tourist product. CARES-310 (camrelizumab plus rivoceranib vs sorafenib) reported OS 23.8 vs 15.2 months — a China-approved first-line combination, not an FDA-interchangeable guarantee. Send triphasic imaging and Child-Pugh labs. About 24 hours. No obligation to book.
Liver: method follows function
On the table after labs
Resection, ablation, TACE/TARE, systemic targeted/IO, selected particle therapy.
Not a tourist SKU
Transplant is policy, not a package. CAR-T is not standard HCC care.
| Question | Usual comparison | Cost note |
|---|---|---|
| Resectable / high-volume HCC | SYSUCC, Shanghai hepatobiliary, CAMS/NCC, Tianjin | OR + function risk — no single band |
| Repeat TACE vs systemic switch | Same public liver units | Session fees vs months of drugs |
| Selected proton / carbon-ion | SPHIC if indication + imaging | ~USD 20-35k course if accepted |
| Fuda name already on the file | Compare method with SYSUCC | Brand is not a price |
What actually changes the plan
📋
Function and burden first
Child-Pugh, portal vein, lesion map, AFP. Without that, every hospital letter is a guess.
🏥
Hepatobiliary volume, not a brand
SYSUCC, Shanghai units, CAMS/NCC, Tianjin. SPHIC only if a beam is the actual question.
✈️
Method-shaped costs
TACE days, systemic months, or a proton calendar. We refuse one HCC package number.
What this page helps you decide
✅
Transplant not sold as tourism
If it is even discussable, it is a policy question, not a landing-page SKU.
💬
Local vs systemic labelled
Ablation/TACE and IO/targeted drugs are different bills and different goals.
🌍
Fuda compared with public liver units
Brand search volume is not liver-function math.
Evidence table
IARC liver deaths, CARES-310 OS, NCCN ablation limits, transplant is not tourism.
| Source | What it says | Relevance to patients |
|---|---|---|
| IARC GLOBOCAN China (2024) | 354,143 cases; 303,783 deaths | HBV-endemic burden. Not a package price. |
| CARES-310, Lancet Oncol (2025 final) | OS 23.8 vs 15.2 months; PFS 5.6 vs 3.7; HR 0.64 | China-approved combo. Hypertension and transaminase toxicity. |
| NCCN ablation notes (current) | Selected small HCC | Not IRE-for-everything. |
| FDA CRLs on the same combo (through 2026) | US file not interchangeable | China label ≠ US label. |
Who this page is for
HCC after several TACE sessions
Need a systemic or particle question answered, not another unnamed embolisation package.
Potentially resectable patients
Need a high-volume hepatobiliary opinion on function and margin, not a brand tour.
Families asking about transplant in China
Need a no-package answer first, then whatever policy path actually exists.
What you can actually book
SYSUCC, Fudan / Eastern Hepatobiliary / Zhongshan, CAMS/NCC. Compare any private local method with a public hepatobiliary unit. Related: Fuda, cancer hub.
Which treatments are discussed, and what decides
For liver cancer, the choice comes down to three questions: how many tumours there are and how big they are, whether the tumour has grown into blood vessels or spread outside the liver, and how well the liver itself still works. Below is a short summary of how Chinese and international guidelines approach this. A doctor proposes the actual plan only after seeing your scans and lab results.
Liver function and cirrhosis
Liver function is scored with the Child-Pugh scale: bilirubin, albumin, blood clotting (INR), ascites (fluid in the abdomen) and hepatic encephalopathy (confusion caused by liver failure). Class A is mild impairment, B is moderate, C is severe.
Cirrhosis on its own does not rule out treatment: almost every active option is designed for class A or B. In class C chemoembolisation is not done, and the discussion usually turns to transplant or supportive care. If the cancer is linked to hepatitis B or C, antiviral treatment continues throughout.
Stages in plain words
0
Very early
One tumour up to 2 cm, no vessel invasion, liver working well, no symptoms.
A
Early
One tumour of any size, or up to three tumours none larger than 3 cm. Liver function preserved.
B
Intermediate
More tumours, but the liver works and there are no cancer symptoms. Chemoembolisation is most often discussed.
C
Advanced
The tumour has grown into vessels or spread outside the liver, but the person can still look after themselves. Drug treatment is discussed.
D
End-stage
Severe symptoms or badly impaired liver function where a transplant is not possible. The focus is supportive care.
A Chinese discharge summary often gives the stage in China’s own system (Ia to IV). It is built on the same factors.
Surgery
Removing part of the liver usually requires class A and enough remaining liver: at least 40% with cirrhosis, at least 30% without. A test before surgery shows how much reserve the liver has. In experienced centres surgery is sometimes discussed in class B, but that decision is individual.
Liver transplant
A transplant treats both the tumour and the diseased liver. It is considered mainly for small tumours when the liver works poorly and removal or ablation is not possible. The usual reference is one tumour up to 5 cm, or up to three tumours no larger than 3 cm, with no invasion of major vessels; China’s guideline proposes wider criteria. Organs are allocated under state rules, so whether a transplant is open to a foreign patient has to be checked separately and early.
Ablation
The tumour is destroyed with heat through a needle guided by ultrasound or CT, using radiofrequency or microwave energy. Ablation suits a single tumour up to 5 cm or 2–3 tumours up to 3 cm, with no invasion of vessels or bile ducts, in class A or B. For tumours up to 3 cm, results are close to surgery with fewer complications. The two methods show no significant difference in results; microwave does better with larger tumours.
Chemoembolisation (TACE)
Chemotherapy is delivered through the artery feeding the tumour, and the vessel is then blocked. It is the main option when there are several tumours still confined to the liver. If the tumour keeps growing after 3–4 sessions, the approach changes: ablation, drugs, radiotherapy or surgery is added.
HAIC: chemotherapy through the liver artery
A catheter is placed in the liver artery and chemotherapy runs continuously for 23–46 hours, without blocking the vessel. It is considered for a large tumour (over 7 cm) that cannot be removed, or for tumour growth into major vessels, when liver function allows. Sessions are usually 3–4 weeks apart, up to 6 in a row. Most experience with this method comes from China; whether it fits your case is for the doctor to decide from your scans.
NanoKnife (irreversible electroporation)
This is another type of ablation, but evidence of its benefit for primary liver cancer is still inadequate, and UK guidance says it should only be used in research. If NanoKnife is offered, ask why standard ablation is not suitable and whether the procedure is part of a study.
Drug treatment
Drugs are discussed when the tumour has grown into vessels or spread outside the liver, or when chemoembolisation is not suitable or has stopped working. The table lists the regimens China’s guideline names for starting drug treatment.
| Regimen | Good to know |
|---|---|
| Atezolizumab + bevacizumab | An upper endoscopy is needed before bevacizumab to check varices and bleeding risk |
| Durvalumab + tremelimumab | Approved in China in 2026; immunotherapy without bevacizumab, side effects need monitoring |
| Nivolumab + ipilimumab | Immunotherapy; side effects need monitoring |
| Camrelizumab + apatinib | Common side effects: high blood pressure, protein in urine, raised liver enzymes |
| Sintilimab, finotonlimab or toripalimab + bevacizumab; anlotinib + penpulimab | Recent Chinese regimens; endoscopy before bevacizumab |
| Lenvatinib | Tablets; in its trial, survival was not inferior to sorafenib |
| Donafenib | Tablets; in its trial, patients lived longer than on sorafenib |
| Tislelizumab | Single-drug immunotherapy |
| Sorafenib | Can be used in class A and B, with more benefit in class A |
| FOLFOX4 chemotherapy | Intravenous chemotherapy |
When liver function is noticeably reduced, data on drug treatment are limited, so the choice needs extra caution. Which option fits your case is decided by an oncologist based on scans, labs and treatment history.
For a free case review, send a three-phase CT or MRI (as DICOM files), bilirubin, albumin and INR results, your hepatitis status and a summary of any treatment so far. A doctor will look at the documents and tell you which options are realistic in your case.
Sources: China’s national liver cancer guideline, European and American guidelines (EASL, AASLD), official drug registration data.
What moves the cost
Liver file review
No charge to start
Function/burden read • Method label • Centre shortlist • Transplant honesty
Coordinated trip
Quoted after records
Hospital matching • Method-shaped drivers • Visa • Interpreter
These are routing steps, not a hospital package SKU. Published procedure examples stay in the evidence/cost sections only when a source exists. Hospital, drugs, stay, interpreter and travel are quoted separately after records.
What happens next
01
Send imaging and liver labs
Plus viral status and prior locoregional/systemic history.
02
Label resectable vs locoregional vs systemic
And say when particle therapy is a real question vs noise.
03
Travel after a liver unit accepts
Invitation, visa, interpreter. Repeat TACE calendars need a longer stay plan.
Request a preliminary case review
Tell us the basics of your case. When you submit, WhatsApp will open with the information you entered so you can review it before sending. This is a preliminary routing request, not a diagnosis, treatment acceptance, trial enrollment, visa decision, or medical advice.
Frequently asked questions
How much is liver cancer treatment in China?
Ablation, TACE, systemic combinations and transplant are different invoices. CARES-310 drugs are a China-labelled option for unresectable HCC, not a flyer price. We itemise after function and stage.
What is CARES-310?
Phase 3 camrelizumab plus rivoceranib vs sorafenib. Final OS 23.8 vs 15.2 months; PFS 5.6 vs 3.7. Approved in China for first-line unresectable HCC. Not an FDA-interchangeable guarantee.
Is NanoKnife standard?
Often investigational or highly selected. Not a pan-HCC substitute.
Can foreigners get a liver transplant in China?
Transplant exists under organ-allocation rules. It is not a standard self-pay walk-in product. We will not sell it as one.
Which hospitals?
SYSUCC, Fudan/Eastern Hepatobiliary/Zhongshan, CAMS/NCC.
What records should I send?
Triphasic CT or MRI, HBV/HCV serology, Child-Pugh labs, AFP, prior TACE dates.
Is Fuda the default liver hospital?
No. Compare any private local method with a public hepatobiliary unit.
Do you promise AFP will fall?
No. Average reply about 24 hours. No obligation to book.
Do I pay before you read the file?
No. Payment required before a file review is a red flag. Average reply about 24 hours. No obligation to book.
How fast do you reply?
About 24 hours. We label the file as labelled care, trial, or marketing. No obligation to book.
Can liver cancer be treated if I have cirrhosis?
Often, yes. Surgery, ablation, chemoembolisation and drugs are designed for people with Child-Pugh class A or B. In class C chemoembolisation is not done, and the discussion usually turns to transplant or supportive care. To assess liver function, send your bilirubin, albumin and INR results and say whether you have ascites or confusion. If you have hepatitis B or C, antiviral treatment continues throughout.
What is HAIC and how is it different from TACE?
In TACE, drugs are injected into the tumour’s artery and the artery is then blocked. In HAIC, a catheter stays in the liver artery and chemotherapy runs continuously for 23–46 hours without blocking the vessel. HAIC is considered for large tumours that cannot be removed or tumours growing into major vessels, when liver function allows. Most experience with it comes from China, and whether it fits your case is for the doctor to decide from your scans.
Red flags in offers
NanoKnife or cryo as the China liver trip, often via Fuda marketing. Transplant sold as walk-in self-pay. Neither is the usual honest desk.
Ablation sold for portal-vein tumour thrombus as a cure.
Transplant quoted as a tourism SKU.
No Child-Pugh, no HBV status on the offer.
Pay before triphasic CT/MRI is read.
Sources
IARC GLOBOCAN 2024 China fact sheet.
Qin et al., CARES-310 final analysis, Lancet Oncology 2025.
NCCN ablation notes; BCLC-style function logic.
Public descriptions of SYSUCC, Fudan/EHBH, CAMS/NCC.
A treating hepatologist or oncologist should review imaging before you travel. This page is matching information, not a treatment recommendation.
Freshness label on this page: 2026-08-15